Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (491-500 of 583) with videos related to

Pageof 59
Sort By:
Journal of Hematology & Oncology|June 24, 2021
A precision medicine classification for treatment of acute myeloid leukemia in older patientsAlice S Mims, Jessica Kohlschmidt, Uma Borate, et al.
Blood|February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Cancer Research|January 13, 1998
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogeneticsM A Caligiuri, M P Strout, D Lawrence, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Haematologica|June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncologyRichard T Hoppe, Ranjana Hira Advani, Philip J Bierman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsGuido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B studyGuido Marcucci, Claudia D Baldus, Amy S Ruppert, et al.
Pageof 59

Showing results (491-500 of 583) with videos related to

Sort By:
Pageof 59
Journal of Hematology & Oncology|June 24, 2021
A precision medicine classification for treatment of acute myeloid leukemia in older patientsAlice S Mims, Jessica Kohlschmidt, Uma Borate, et al.
Blood|February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Cancer Research|January 13, 1998
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogeneticsM A Caligiuri, M P Strout, D Lawrence, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Haematologica|June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncologyRichard T Hoppe, Ranjana Hira Advani, Philip J Bierman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsGuido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B studyGuido Marcucci, Claudia D Baldus, Amy S Ruppert, et al.
Pageof 59